References from A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies. Local targets link to admitted publications; unresolved targets remain external evidence.
No reference evidence is available for this admitted work.
References for A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies | ResearchHub - ResearchHub
